*
`
`Ov
`
`HOME (cid:9)
`
`ONLINE
`STORE (cid:9)
`
`About Siet-p - its fret!
`Join, day!
`
`CHATS
`
`MC MEEC SH C
`
`An Interview with Orphan Medical about Xyremfi
`
`tvtnneapolls, MN - February 12, 2001
`
`Waiting for Xyrern
`
`
`
`Persons with narcolepsy, especially those who experience cataplexy, are anxiously awaiting the decision by the Food and Drug
`Administration (FDA) on the approval of Xyremfi as a treatment for the symptoms of narcolepsy. A decision is expected later this spring,
`as the Xyremfi New Drug Application has been given Priority ReAew Status.
`
`As a result, there are a number of questions being raised by those most interested in Xyrem. Naturally, many of these have come up in
`our regularly scheduled Narcolepsy Chats, so TalkAboutSleep contacted Orphan Medical, the company developing Xyrem, to get some
`answers. Several individuals from the Orphan Medical corporate staff were kind enough to respond, including CEO John Bullion, Chief
`Operating Officer William Houghton M.D., and Vice President of Marketing Patti Engel.
`
`The interview covered a number of topics, including availability, cost, medical education, and "how it works". We hope you enjoy reading
`this interview and find the information helpful to you.
`
`Availability of Xyren1
`
`TalkAboutSleep: Can you summarize the current status of Xyrem and the NDA? When do you expect the FDA to complete its review?
`With FDA approval, how long will it be before Xyrom will be available for doctors to prescribe?
`
`Orphan Medical, John Bullion, CEO: Orphan Medical filed the New Drug Application (NDA) on October 2, 2000, and the application was
`granted priority review status on October 10, 2000. There will also be an advisory committee meeting on March 15, to discuss Xyrem.
`Based on the priority status, the FDA is expected to pro4de a decision regarding the NDA by April 2 of this year.
`
`The Company expects that Xyrem will be available for patients within a few weeks following the approval with a full launch campaign and
`education materials for physicians coming a few months after the approval.
`
`TalkAboutSleep: Will Xyrem be available in pharmacies? Can you describe how the distribution of Xyrem will occur? Is this part of the
`FDA decision process? Or are there other regulatory groups involved in this process?
`
`Orphan Medical, Patti Engel, Vice President: Xyrem will be available through a specialty distribution system that will utilize a central
`pharmacy that will handle the delivery of medicine to the patients.
`
`To order Xyrem, a physician will write a prescription and fax that to the central pharmacy. That pharmacy will process the prescription
`request, call the physician to verify the prescription, call the patient to assist them in gaining coverage from their insurance company, and
`then set up a delivery time directly to the patient so that they may receive their medicine.
`
`This system was designed by Orphan Medical with assistance and input from State Scheduling authorities, experts in specialty
`distribution, drug diversion investigators, field law enforcement, narcolepsy patient groups, and pharmacists experienced in dealing with
`Scheduled medicines.
`
`TalkAboutSleep: What progress is being made on the state regulations where GHB is still "outlawed"? Will people who reside in states
`with stricter regulation than the federal rules simply not be able to use Xyrem?
`
`Orphan Medical, Patti Engel, Vice President: The federal law allows for patients to have Xyrem as prescribed by their doctor. As of this
`writing, many states have adopted this stance: a few are waiting for formal FDA approval. Once approved, patients can call 1-888-
`8ORPHAN to determine Xyrem’s status in their particular state.
`
`Pricinq and Insurance
`
`Talk.AboutSleep: What is the estimated cost to Narcolepsy patients? Is it likely that the drug will be covered by health insurers? Will
`Orphan Medical provide assistance to persons with narcolepsy in getting insurance coverage? Will Xyrem be available free or at a reduced
`cost to low-income individuals without insurance? How will this be done?
`
`Orphan Medical, Patti Engel, Vice President: Because the handling requirements are not yet finalized by the FDA, there is not yet a
`price established for Xyrem. That will be determined nearer the time of approval. If approved, Xyrem will likely be covered by many health
`insurance plans and our Reimbursement Services department will be available to assist patients that are working with their plans to obtain
`coverage.
`
`AMN1033
`IPR of U.S. Patent No. 7,765,107
`Page 1 of 2
`
`

`

`For patients who are uninsured or need financial assistance to obtain Xyrern, there will be a patient assistance program administered
`through the National Organization for Rare Disorders (NORD) and they will determine the eligibility for patients based on their financial
`status.
`
`How Does Xyrem Work?
`TalkAboutSleep: Originally Xyrom was expected to be a drug for the control of cataplexy for people who have Narcolepsy. We know from
`personal experiences that it can also help atleiate Excessive Daytime Sleepiness (EDS). Does Orphan Medical know exactly how Xyrem
`alleates cataplexy? Is it a chemical effect or does it occur purely by improving sleep?
`
`Orphan Medical, William Houghton, MD, COO: The ultimate mechanism of action is not known. Many of the biochemical changes in
`the brain have been identified in terms of modulation of levels of important chemicals and neurotransmitter functions in the brain. As well,
`primary effects of improved sleep architecture occur that may contribute to why Xyrem reaches its optimal results after 8 to 12 weeks. It
`stands to reason that maintained changes in sleep contribute to improve daytime functioning, but further research into the science of
`narcolepsy is required.
`
`TalkAboutSleep: With the improvement in EDS that many with narcolepsy experience, has Xyrem been tested on those who don’t have
`cataplexy or those with a diagnosis of Idiopathic Hypersomnolenco? If so, haw these patients also experienced improvement in their EDS?
`
`Orphan Medical, WillIam Houghton, MD, COO: No, weve been entirely focused on narcolepsy and entry into the clinical trials has been
`designed to include cataplexy as a diagnosis for narcolepsy. We\e not investigated Xyrem for the potential use in other sleep disorders.
`
`TalkAboutSleep: Over the years of testing, have any negative side effects of)’jrem been found?
`
`Orphan Medical, William Houghton, MD, COO: The side effects seen in the trials have been generally minor in nature and tend to abate
`or time and have included headache, nausea, dizziness, enuresis, and sleepwalking.
`
`Medical Education
`TalkAboutSleep: Unfortunately, so many of the doctors who treat patients with Narcolepsy around the country do not keep up with current
`research and are unaware of the success so many with Narcolepsy have had with Xyrem. Will Orphan Medical have information available to
`doctors? Will there be an education program for those who may be reluctant to prescribe it?
`
`Orphan Medical, Patti Engel, Vice President: Information on Xyrem will be available to physicians through printed material, participation
`at medical meetings, and through representatives of Orphan Medical that will be able to discuss the details of Xyrem.
`
`There is also a program called the Xyrem Physician Success Program that will ensure that a physician understands the unique nature of
`Xyrem and how the prescription and distribution process works to provide this medicine to the patients that need it in a responsible
`manner.
`
`TalkAboutSleep: Thank you, Orphan Medical, for answering these questions about Xyrem() for our audience.
`
`NI:
`
`Fisher &Paykel
`
`1f! ,ALT " CA.R LE
`
`..3uietsleep’
`
`I (PA1iUow
`
`t!sie’Online Store (cid:9)
`
`Message Boards !Sleep Chats Members h ip lParth (cid:9)
`
`About Us
`
`El 2000-2012 TALK ABOVE SLEEP, INC. ALL REEF-ifS RESERVE.
`
`AMN1033
`IPR of U.S. Patent No. 7,765,107
`Page 2 of 2
`
`